Literature DB >> 2932883

Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function.

M Onsrud, E Paus, E Haug, K Kjørstad.   

Abstract

A radio-immunoassay for the determination of the serum concentration of hydroxyprogesterone caproate (HPC) was established. After a single intramuscular injection of 1000 mg, the mean serum level reached its maximum (44-81 nmol/l) after 2-7 days. Patients on long-term adjuvant HPC treatment (consisting of 1000 mg daily for 5 days followed by 1000 mg every 2 weeks) presented peak hormone levels 2 weeks after commencing treatment. After a drop at 5 weeks, the mean serum level slowly increased again to 130 nmol/l after 25 weeks of treatment. Patients being treated with weekly injections had significantly higher serum levels than those treated every 2 weeks. Considerable inter-individual differences were observed. The serum concentrations of HPC measured in this study compare favorably with those previously found in patients treated with medroxyprogesterone acetate. The patients on adjuvant HPC showed no significant change in the levels of cortisol, dehydroepiandrosterone sulphate, androstenedione, or estrone during the first 25 weeks of treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932883     DOI: 10.3109/00016348509156732

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  16 in total

1.  Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats.

Authors:  Imam H Shaik; Jaime R Bastian; Yang Zhao; Steve N Caritis; Raman Venkataramanan
Journal:  Xenobiotica       Date:  2015-07-07       Impact factor: 1.908

Review 2.  17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.

Authors:  Emma D Deeks
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

Review 3.  Progestin treatment for the prevention of preterm birth.

Authors:  Miha Lucovnik; Ruben J Kuon; Linda R Chambliss; William L Maner; Shao-Qing Shi; Leili Shi; James Balducci; Robert E Garfield
Journal:  Acta Obstet Gynecol Scand       Date:  2011-06-27       Impact factor: 3.636

4.  Metabolism of 17-alpha-hydroxyprogesterone caproate by human placental mitochondria.

Authors:  Valentina M Fokina; Olga L Zharikova; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Reprod Sci       Date:  2011-12-02       Impact factor: 3.060

5.  Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.

Authors:  Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Dwight J Rouse; Alan M Peaceman; Anthony Sciscione; Catherine Y Spong; Michael W Varner; Fergal D Malone; Jay D Iams; Brian M Mercer; John M Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper
Journal:  Am J Obstet Gynecol       Date:  2011-03-22       Impact factor: 8.661

6.  Development and validation of a high-performance liquid chromatography-mass spectrometric assay for the determination of 17alpha-hydroxyprogesterone caproate (17-OHPC) in human plasma.

Authors:  Shimin Zhang; Sripal Reddy Mada; Don Mattison; Steve Caritis; Raman Venkataramanan
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-06-02       Impact factor: 3.205

7.  Transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate.

Authors:  Sarah J Hemauer; Ru Yan; Svetlana L Patrikeeva; Donald R Mattison; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Am J Obstet Gynecol       Date:  2008-08       Impact factor: 8.661

8.  The role of progesterone in prevention of preterm birth.

Authors:  Jodie M Dodd; Caroline A Crowther
Journal:  Int J Womens Health       Date:  2010-08-09

9.  Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.

Authors:  Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Gary D Hankins; Menachem Miodovnik; Mary F Hebert; Jason G Umans; Thomas Benedetti; Donald Mattison; Anne Zajicek; Dawn Fischer; Aimee Jackson
Journal:  Am J Obstet Gynecol       Date:  2012-08-16       Impact factor: 8.661

10.  Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety.

Authors:  Helen Y How; Baha M Sibai
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.